知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

221 条记录 (耗时 0.033 秒)

    Treatment for pulmonary hypertension
    11.
    发明授权
    Treatment for pulmonary hypertension 有权
    治疗肺动脉高压

    公开(公告)号：US08969409B2

    公开(公告)日：2015-03-03

    申请号：US13899734

    申请日：2013-05-22

    申请人： United Therapeutics Corporation

    发明人： Martine A. Rothblatt ,  Lewis J. Rubin

    IPC分类号： A61K31/34

    CPC分类号： A61K31/5585 ,  A61K31/513 ,  A61K31/522 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5578 ,  A61K2300/00

    摘要： One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.

    摘要翻译： 一个实施方案涉及一种治疗肺动脉高压的方法，其基于与有需要的受试者共同施用药物有效量的用于治疗肺动脉高压的口服治疗剂和药学有效量的用于治疗肺动脉高压的吸入治疗剂。 这些药物的共同给药的益处是消除或减少与任一药物的单一疗法相关的一种或多种副作用，以及与其它给药途径相关的一种或多种副作用，例如皮下或静脉内给药。

    METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF
    14.
    发明申请
    METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF 审中-公开
    治疗患者发生ISCHEMIC事件及化合物发生风险的方法

    公开(公告)号：US20130040898A1

    公开(公告)日：2013-02-14

    申请号：US13643366

    申请日：2011-04-29

    申请人： Pär Johansson

    发明人： Pär Johansson

    IPC分类号： A61K38/12 ,  A61P9/10

    CPC分类号： A61K31/5578 ,  A61K31/557 ,  A61K31/5585 ,  A61K33/00 ,  A61K38/08 ,  A61K38/465 ,  A61K38/58 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and/or no-reflow phenomena and/or ischemia-reperfusion injury by administration of agent(s) modulating and/or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb/IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine, Beta-blockers and surgical methods such as percutaneous coronary intervention (PCI), PCI with thrombus aspiration, PCI with stents.

    摘要翻译： 本发明涉及用于治疗的化合物，其用于保护内皮，防止微循环中的病理性血栓形成并保留血小板数量和功能，因此可能与心血管疾病患者的缺血事件的治疗或预防有关。 本发明对于具有或具有发展缺血性事件（例如急性心肌梗塞和/或无复流现象和/或缺血 - 再灌注损伤）的风险增加的患者特别有用，其通过施用调节剂和/ 或保持内皮完整性。 化合物可以与急性心血管缺血事件如血小板抑制剂如阿司匹林（ASA），噻吩并吡啶类，GPIIb / IIIa抑制剂的标准治疗组合施用，胃肠外抗凝剂如未分级肝素（UFH），比伐卢定，依诺肝素和磺达肝素 ，维拉帕米，腺苷，硝普钠，硝酸甘油，肾上腺素，β受体阻滞剂和外科手术如经皮冠状动脉介入PCI（PCI），血栓抽吸PCI，支架PCI。

    Epoprostenol formulation and method of making thereof
    16.
    发明授权
    Epoprostenol formulation and method of making thereof 有权
    Eroprostenol制剂及其制备方法

    公开(公告)号：US08318802B2

    公开(公告)日：2012-11-27

    申请号：US12278061

    申请日：2007-02-02

    申请人： Naglesh R. Palepu

    发明人： Naglesh R. Palepu

    IPC分类号： A01N43/08 ,  A61K31/34

    CPC分类号： A61K9/19 ,  A61K9/0019 ,  A61K31/557 ,  A61K31/5585 ,  A61K47/183 ,  A61K47/26

    摘要： This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.

    摘要翻译： 本发明涉及一种稳定的前荚MP素组合物，其可与市售IV液体组合，并且可以在约15-30℃的环境条件下以其重构和/或稀释形式施用大于24小时。 组合物优选含有（a）依前列醇或其盐; （b）碱化剂; 和（c）碱，使得当重构或溶解时，溶液的pH> 11。 还公开了制备冻干组合物的方法。

    Inhalable Formulations For Treating Pulmonary Hypertension And Methods Of Using Same
    18.
    发明申请
    Inhalable Formulations For Treating Pulmonary Hypertension And Methods Of Using Same 审中-公开
    用于治疗肺动脉高压的可吸入制剂及其使用方法

    公开(公告)号：US20110265786A1

    公开(公告)日：2011-11-03

    申请号：US13020429

    申请日：2011-02-03

    申请人： Imtiaz Chaudry

    发明人： Imtiaz Chaudry

    IPC分类号： A61M11/00 ,  A61K31/40 ,  A61P11/00 ,  A61K31/472 ,  A61K31/405 ,  A61K31/403 ,  A61K31/55 ,  A61K31/675

    CPC分类号： A61K9/0078 ,  A61K31/00 ,  A61K31/401 ,  A61K31/404 ,  A61K31/472 ,  A61K31/55 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/675 ,  A61K38/556 ,  A61K45/06

    摘要： The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.

    摘要翻译： 本发明涉及用于治疗哺乳动物（例如人）中的肺动脉高压的可吸入制剂，其中所述制剂包含至少一种高血压减轻剂，包括但不限于血管紧张素转换酶抑制剂，血管紧张素受体阻断剂， β-阻滞剂，钙通道阻滞剂或血管扩张剂，或其任何组合。 本发明的制剂可以是溶液或悬浮液，并且优选适于通过雾化进行给药。 本发明还涉及用于治疗患有肺动脉高压的哺乳动物的方法和试剂盒。

    Inhalable formulations for treating pulmonary hypertension and methods of using same
    20.
    发明申请
    Inhalable formulations for treating pulmonary hypertension and methods of using same 审中-公开
    用于治疗肺动脉高压的可吸入制剂及其使用方法

    公开(公告)号：US20040265238A1

    公开(公告)日：2004-12-30

    申请号：US10609233

    申请日：2003-06-27

    发明人： Imtiaz Chaudry

    IPC分类号： A61K031/554 ,  A61K031/455 ,  A61K031/401 ,  A61K031/137

    CPC分类号： A61K9/0078 ,  A61K31/00 ,  A61K31/401 ,  A61K31/404 ,  A61K31/472 ,  A61K31/55 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/675 ,  A61K38/556 ,  A61K45/06

    摘要： The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.

    摘要翻译： 本发明涉及用于治疗哺乳动物（例如人）中的肺动脉高压的可吸入制剂，其中所述制剂包含至少一种高血压减轻剂，包括但不限于血管紧张素转换酶抑制剂，血管紧张素受体阻断剂， β-阻滞剂，钙通道阻滞剂或血管扩张剂，或其任何组合。 本发明的制剂可以是溶液或悬浮液，并且优选适于通过雾化进行给药。 本发明还涉及用于治疗患有肺动脉高压的哺乳动物的方法和试剂盒。